chimerix_logo.jpg
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2024 16h05 HE | Chimerix, Inc.
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to...
chimerix_logo.jpg
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
30 mai 2024 07h00 HE | Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
chimerix_logo.jpg
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
01 mai 2024 07h00 HE | Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
chimerix_logo.jpg
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
24 avr. 2024 07h00 HE | Chimerix, Inc.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 avr. 2024 16h05 HE | Chimerix, Inc.
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards...
chimerix_logo.jpg
Chimerix Appoints Marc D. Kozin to Board of Directors
21 mars 2024 07h00 HE | Chimerix, Inc.
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
29 févr. 2024 07h00 HE | Chimerix, Inc.
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204...
chimerix_logo.jpg
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
27 févr. 2024 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
22 févr. 2024 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Appoints Lisa Decker to Board of Directors
29 déc. 2023 07h00 HE | Chimerix, Inc.
DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...